Prognostic markers for CLL - how do they help determine who gets which treatment?
PET-CT vs MRI in multiple myeloma
Daratumumab in multiple myeloma: an overview of 3 key trials
Niels van de Donk
Temsirolimus with BERT for the treatment of relapsed mantle cell and follicular lymphoma
How can MRD and disease be assessed in routine practice?